1310350-45-8

Basic information

• Product Name: (R)-4-(5-amino-2-fluorophenyl)-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine
• Synonyms: (R)-4-(5-amino-2-fluorophenyl)-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine
• CAS NO: 1310350-45-8
• Molecular Weight: 259.231
• Mol File: 1310350-45-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (R)-4-(5-amino-2-fluorophenyl)-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-(5-amino-2-fluorophenyl)-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine(1310350-45-8)
• EPA Substance Registry System: (R)-4-(5-amino-2-fluorophenyl)-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine(1310350-45-8)

Safety Data

• Hazardous Substances Data: 1310350-45-8(Hazardous Substances Data)

Upstream product

• 79110-05-7 1-(2-fluoro-5-nitrophenyl)ethanone 
• 1075231-02-5 (R)-2,2-difluoro-3-(2-fluoro-5-nitrophenyl)-3-((R)-2-methylpropane-2-sulfinylamino)butyric acid ethyl ester 
• 1075231-03-6 (R)-2-methylpropane-2-sulfinic acid [(R)-2,2-difluoro-1-(2-fluoro-5-nitrophenyl)-3-hydroxy-1-methylpropyl]amide 
• 1075231-04-7 (R)-3-amino-2,2-difluoro-3-(2-fluoro-5-nitrophenyl)butan-1-ol 
• 1075230-62-4 (R)-2-methylpropane-2-sulfinic acid [1-(2-fluoro-5-nitrophenyl)-(E)-ethylidene]amide 
• 1310350-22-1 (R)-5,5-difluoro-4-(2-fluoro-5-nitrophenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 1310350-60-7 {(R)-4-[5-(benzhydrylidene-amino)-2-fluoro-phenyl]-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl}-[bis-(4-methoxy-phenyl)-phenyl-methyl]-amine 

Downstream Products

• 1310347-25-1 5-chloro-pyridine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 
• 1310350-58-3 (R)-4-(5-amino-2-fluoro-4-iodophenyl)-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 1414876-67-7 (R)-5,5-difluoro-4-[5-fluoro-2-(4-methoxy-benzyl)-1H-indol-6-yl]-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 1310348-31-2 5-chloro-pyrazine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 
• 1415914-08-7 [⁽³⁾H]-(R)-4-(5-amino-2-fluoro-phenyl)-5,5-difluoro-4-methyl-5 ,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 1415914-06-5 [⁽³⁾H]-5-but-2-ynyloxy-pyrazine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 
• 1415914-09-8 ((R)-4-{5-[(5-chloro-pyrazine-2-carbonyl)-amino]-2-fluoro-phenyl}-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl)-carbamic acid tert-butyl ester 
• 1415914-10-1 ((R)-5,5-difluoro-4-{2-fluoro-5-[(5-prop-2-ynyloxy-pyrazine-2-carbonyl)-amino]-phenyl}-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl)-carbamic acid tert-butyl ester 
• 1415914-11-2 (R)-N-(3-(2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(prop-2-ynyloxy)pyrazine-2-carboxamide 
• 1415914-12-3 (R)-N-(3-(2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(3-(tributylstannyl)prop-2-ynyloxy)pyrazine-2-carboxamide 
• 1415914-05-4 5-but-2-ynyloxy-pyrazine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 
• 1310348-72-1 1-difluoromethyl-1H-pyrazole-3-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 
• 1310347-64-8 4-chloro-1-methyl-1H-pyrazole-3-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 
• 1310348-70-9 1-methyl-1H-pyrazole-3-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 

Relevant articles and documents

β-secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease

An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and

1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS

The present invention provides compounds of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present inv

2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES

The present invention relates to 2-Amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutical